Form 4: Akero Therapeutics Chief Scientific Officer Timothy Rolph Donates 14,100 Shares

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, donated 14,100 shares of common stock to a donor advised fund on December 26, 2024.

Summary

• Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, donated 14,100 shares of the company's common stock.
• The transaction occurred on December 26, 2024.
• The shares were donated to a donor advised fund.
• Following the transaction, Mr. Rolph beneficially owns 184,237 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock donation, with no positive or negative implications for the company's performance.

Industry Context

This is a routine Form 4 filing, which is common for company insiders who make transactions involving their company's stock. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is similar to those of other executives at comparable companies.
• The donation of shares to a donor advised fund is a common practice for executives and does not indicate any unusual activity.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a donation of shares by an executive and does not affect the company's financials or operations.

Key Dates

Keywords

Akero Therapeutics, Timothy Rolph, Chief Scientific Officer, stock donation, donor advised fund, insider transaction, share ownership